| Identification | Back Directory | [Name]
BMX-IN-1 | [CAS]
1431525-23-3 | [Synonyms]
henyl]-
BMX-IN-1
BMX inhibitor 1
BMX-IN-1 USP/EP/BP
BMX kinase inhibitor
BMX-IN-1
(BMX kinase inhibitor
6]naphthyridin-1(2H)-yl)phenyl)acrylamide
N-(2-methyl-5-(9-(4-(methylsulfonamido)phenyl)-2-oxobenzo[h][1
N-(2-Methyl-5-(9-(4-(MethylsulfonaMido)phenyl)-2-oxobenzo[h][1,6]naphthyridin-1(2H)-yl)phenyl)acrylaMide
BMX-INQ: What is
BMX-IN Q: What is the CAS Number of
BMX-IN Q: What is the storage condition of
BMX-IN
N-[2-Methyl-5-[9-[4-[(methylsulfonyl)amino]phenyl]-2-oxobenzo[h]-1,6-naphthyridin-1(2H)-yl]phenyl]-2-propenamide
2-Propenamide, N-[2-methyl-5-[9-[4-[(methylsulfonyl)amino]phenyl]-2-oxobenzo[h]-1,6-naphthyridin-1(2H)-yl]phenyl]-
BMX KINASE INHIBITOR;N-(2-METHYL-5-(9-(4-(METHYLSULFONAMIDO)PHENYL)-2-OXOBENZO[H][1;6]NAPHTHYRIDIN-1(2H)-YL)PHENYL)ACRYLAMIDE | [Molecular Formula]
C29H24N4O4S | [MDL Number]
MFCD25372042 | [MOL File]
1431525-23-3.mol | [Molecular Weight]
524.59 |
| Chemical Properties | Back Directory | [density ]
1.397±0.06 g/cm3(Predicted) | [storage temp. ]
Store at -20°C | [solubility ]
insoluble in H2O; insoluble in EtOH; ≥5.25 mg/mL in DMSO | [form ]
solid | [pka]
7.77±0.10(Predicted) | [color ]
White to yellow |
| Hazard Information | Back Directory | [Description]
BMX-IN-1 is a selective, irreversible inhibitor of bone marrow tyrosine kinase on chromosome X (BMX; IC50 = 8 nM) that targets Cys496 in the BMX ATP binding domain. It additionally targets the related Bruton’s tyrosine kinase (BTK) with an IC50 value of 10.4 nM, but is more than 47-656-fold less potent for inhibition of Blk, JAK3, EGFR, Itk, or Tec activity. BMX-IN-1 was shown to inhibit the proliferation of Tel-BMX-transformed Ba/F3 prostate cancer cells with a GI50 value of 25 nM. Antiproliferative activity was also observed in RV-1, DU-145, PC-3, and VCAP prostate cancer cell lines (GI50s = 2.54, 4.38, 5.37, and 2.46 μM, respectively). | [Uses]
BMX-IN-1 is a selective, irreversible inhibitor of bone marrow tyrosine kinase on chromosome X (BMX) that targets Cys496 in the BMX ATP binding domain with an IC50 of 8 nM, also targets the related Bruton’s tyrosine kinase (BTK) with an IC50 value of 10.4 nM, but is more than 47-656-fold less potent against Blk, JAK3, EGFR, Itk, or Tec activity. | [target]
BMX Kinase | [storage]
Store at -20°C | [References]
[1] Feiyang Liu , et al. Discovery of a Selective Irreversible BMX Inhibitor for Prostate Cancer. ACS Chem. Biol., DOI: 10.1021/cb4000629 |
|
| Company Name: |
BOC Sciences
|
| Tel: |
1-631-485-4226; 16314854226 |
| Website: |
https://www.bocsci.com |
|